National Institute of Allergy and Infectious Diseases (NIAID): Multiple Sclerosis trials
The registry lists 14 Multiple Sclerosis studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 2 are open to participants now and 6 have results posted.
Phase 1 5Phase 2 8Phase 4 1No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)RecruitingNCT03109288Phase 1/2
- Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous SystemRecruitingNCT00794352
- COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedNCT05000216Phase 2Results posted
- Idebenone for Primary Progressive Multiple SclerosisCompletedNCT01854359Phase 1/2Results posted
- A Cooperative Clinical Study of Abatacept in Multiple SclerosisCompletedNCT01116427Phase 2Results posted
- Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)CompletedNCT00950248Phase 1/2Results posted
- High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) StudyCompletedNCT00288626Phase 2Results posted
- Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple SclerosisCompletedNCT00094172Phase 2Results posted
- Ocrelizumab Discontinuation in Relapsing Multiple SclerosisActive, not recruitingNCT05285891Phase 4
- Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple SclerosisCompletedNCT02330965
- T and B Cell Responses in Autoimmune DiseasesTerminatedNCT01947036
- Treating Multiple Sclerosis With Sirolimus, an Immune System SuppressorTerminatedNCT00095329Phase 1/2
- Safety of RG2077 in Patients With Multiple SclerosisCompletedNCT00076934Phase 1
- Treatment of Multiple Sclerosis With Copaxone and AlbuterolCompletedNCT00039988Not applicable